Do analysts recommend IFRX or LTRN?

InflaRx presently has a consensus price target of $7.33, suggesting a potential upside of 263.94%. Given InflaRx's stronger consensus rating and higher probable upside, equities research analysts clearly believe InflaRx is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InflaRx 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.88 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is IFRX or LTRN more profitable?

InflaRx's return on equity of -53.56% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% Lantern Pharma N/A -198.34% -129.08%

Does the media refer more to IFRX or LTRN?

In the previous week, InflaRx had 7 more articles in the media than Lantern Pharma. MarketBeat recorded 11 mentions for InflaRx and 4 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.94 beat InflaRx's score of 0.91 indicating that Lantern Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend EQ or LTRN?

Equillium presently has a consensus price target of $7.57, indicating a potential upside of 225.65%. Given Equillium's stronger consensus rating and higher possible upside, equities research analysts plainly believe Equillium is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Equillium 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.91 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is EQ or LTRN more profitable?

Equillium's return on equity of -61.43% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Equillium N/A -61.43% -53.72% Lantern Pharma N/A -198.34% -129.08%

Does the media refer more to EQ or LTRN?

In the previous week, Equillium had 3 more articles in the media than Lantern Pharma. MarketBeat recorded 7 mentions for Equillium and 4 mentions for Lantern Pharma. Equillium's average media sentiment score of 1.56 beat Lantern Pharma's score of 0.94 indicating that Equillium is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate LTRN or NGEN?

NervGen Pharma has a consensus target price of $14.00, suggesting a potential upside of 711.59%. Given NervGen Pharma's stronger consensus rating and higher probable upside, analysts clearly believe NervGen Pharma is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NervGen Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.83

Which has preferable valuation and earnings, LTRN or NGEN?

NervGen Pharma is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantern Pharma N/A N/A -$17.12M -$1.45 N/A NervGen Pharma N/A N/A -$31.58M -$0.09 N/A

Is LTRN or NGEN more profitable?

Lantern Pharma's return on equity of -198.34% beat NervGen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lantern Pharma N/A -198.34% -129.08% NervGen Pharma N/A -3,272.64% -228.15%

Does the media favor LTRN or NGEN?

In the previous week, NervGen Pharma had 1 more articles in the media than Lantern Pharma. MarketBeat recorded 5 mentions for NervGen Pharma and 4 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.94 beat NervGen Pharma's score of -0.13 indicating that Lantern Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NervGen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend HURA or LTRN?

TuHURA Biosciences currently has a consensus target price of $9.00, suggesting a potential upside of 268.85%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe TuHURA Biosciences is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TuHURA Biosciences 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, HURA or LTRN?

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TuHURA Biosciences N/A N/A -$30.05M -$0.61 N/A Lantern Pharma N/A N/A -$17.12M -$1.45 N/A

Is HURA or LTRN more profitable?

TuHURA Biosciences' return on equity of -156.12% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.12% -105.38% Lantern Pharma N/A -198.34% -129.08%

Does the media refer more to HURA or LTRN?

In the previous week, TuHURA Biosciences had 1 more articles in the media than Lantern Pharma. MarketBeat recorded 5 mentions for TuHURA Biosciences and 4 mentions for Lantern Pharma. TuHURA Biosciences' average media sentiment score of 1.69 beat Lantern Pharma's score of 0.94 indicating that TuHURA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CNTB or LTRN?

Connect Biopharma currently has a consensus price target of $7.43, indicating a potential upside of 193.62%. Given Connect Biopharma's stronger consensus rating and higher possible upside, research analysts clearly believe Connect Biopharma is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Connect Biopharma 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CNTB or LTRN more profitable?

Connect Biopharma's return on equity of -147.87% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Connect Biopharma N/A -147.87% -112.79% Lantern Pharma N/A -198.34% -129.08%

Does the media favor CNTB or LTRN?

In the previous week, Connect Biopharma had 3 more articles in the media than Lantern Pharma. MarketBeat recorded 7 mentions for Connect Biopharma and 4 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.94 beat Connect Biopharma's score of 0.68 indicating that Lantern Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lantern Pharma (LTRN) Competitors

$2.65 +0.02 (+0.76%)

Closing price 04:00 PM Eastern

Extended Trading

$2.67 +0.02 (+0.75%)

As of 04:10 PM Eastern

Compare

LTRN vs. IFRX, EQ, NGEN, HURA, and CNTB

Should you buy Lantern Pharma stock or one of its competitors? Lantern Pharma's main competitors and comparable companies include InflaRx (IFRX), Equillium (EQ), NervGen Pharma (NGEN), TuHURA Biosciences (HURA), and Connect Biopharma (CNTB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lantern Pharma compare to InflaRx?

InflaRx (NASDAQ:IFRX) and Lantern Pharma (NASDAQ:LTRN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

42.4% of InflaRx shares are held by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are held by institutional investors. 16.3% of InflaRx shares are held by company insiders. Comparatively, 8.5% of Lantern Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

InflaRx has a beta of 2.48, meaning that its share price is 148% more volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.34, meaning that its share price is 134% more volatile than the broader market.

In the previous week, InflaRx had 7 more articles in the media than Lantern Pharma. MarketBeat recorded 11 mentions for InflaRx and 4 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.94 beat InflaRx's score of 0.91 indicating that Lantern Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InflaRx	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantern Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

InflaRx's return on equity of -53.56% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
Lantern Pharma	N/A	-198.34%	-129.08%

Lantern Pharma has lower revenue, but higher earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	9,892.98	-$51.63M	-$0.58	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A

InflaRx presently has a consensus price target of $7.33, suggesting a potential upside of 263.94%. Given InflaRx's stronger consensus rating and higher probable upside, equities research analysts clearly believe InflaRx is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

InflaRx beats Lantern Pharma on 12 of the 15 factors compared between the two stocks.

How does Lantern Pharma compare to Equillium?

Equillium (NASDAQ:EQ) and Lantern Pharma (NASDAQ:LTRN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Lantern Pharma has lower revenue, but higher earnings than Equillium. Equillium is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	3.58	-$22.40M	-$0.32	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A

Equillium presently has a consensus price target of $7.57, indicating a potential upside of 225.65%. Given Equillium's stronger consensus rating and higher possible upside, equities research analysts plainly believe Equillium is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Equillium had 3 more articles in the media than Lantern Pharma. MarketBeat recorded 7 mentions for Equillium and 4 mentions for Lantern Pharma. Equillium's average media sentiment score of 1.56 beat Lantern Pharma's score of 0.94 indicating that Equillium is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lantern Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Equillium's return on equity of -61.43% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-61.43%	-53.72%
Lantern Pharma	N/A	-198.34%	-129.08%

27.1% of Equillium shares are held by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are held by institutional investors. 17.8% of Equillium shares are held by company insiders. Comparatively, 8.5% of Lantern Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Equillium has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.34, meaning that its share price is 134% more volatile than the broader market.

Summary

Equillium beats Lantern Pharma on 11 of the 15 factors compared between the two stocks.

How does Lantern Pharma compare to NervGen Pharma?

Lantern Pharma (NASDAQ:LTRN) and NervGen Pharma (NASDAQ:NGEN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

Lantern Pharma's return on equity of -198.34% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-198.34%	-129.08%
NervGen Pharma	N/A	-3,272.64%	-228.15%

28.6% of Lantern Pharma shares are held by institutional investors. 8.5% of Lantern Pharma shares are held by insiders. Comparatively, 5.8% of NervGen Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NervGen Pharma has a consensus target price of $14.00, suggesting a potential upside of 711.59%. Given NervGen Pharma's stronger consensus rating and higher probable upside, analysts clearly believe NervGen Pharma is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

NervGen Pharma is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A
NervGen Pharma	N/A	N/A	-$31.58M	-$0.09	N/A

In the previous week, NervGen Pharma had 1 more articles in the media than Lantern Pharma. MarketBeat recorded 5 mentions for NervGen Pharma and 4 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.94 beat NervGen Pharma's score of -0.13 indicating that Lantern Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantern Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NervGen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lantern Pharma beats NervGen Pharma on 7 of the 13 factors compared between the two stocks.

How does Lantern Pharma compare to TuHURA Biosciences?

TuHURA Biosciences (NASDAQ:HURA) and Lantern Pharma (NASDAQ:LTRN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

In the previous week, TuHURA Biosciences had 1 more articles in the media than Lantern Pharma. MarketBeat recorded 5 mentions for TuHURA Biosciences and 4 mentions for Lantern Pharma. TuHURA Biosciences' average media sentiment score of 1.69 beat Lantern Pharma's score of 0.94 indicating that TuHURA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TuHURA Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lantern Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 6.1% of TuHURA Biosciences shares are owned by insiders. Comparatively, 8.5% of Lantern Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

TuHURA Biosciences has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.34, indicating that its stock price is 134% more volatile than the broader market.

TuHURA Biosciences currently has a consensus target price of $9.00, suggesting a potential upside of 268.85%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe TuHURA Biosciences is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TuHURA Biosciences' return on equity of -156.12% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.12%	-105.38%
Lantern Pharma	N/A	-198.34%	-129.08%

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A

Summary

TuHURA Biosciences beats Lantern Pharma on 8 of the 13 factors compared between the two stocks.

How does Lantern Pharma compare to Connect Biopharma?

Connect Biopharma (NASDAQ:CNTB) and Lantern Pharma (NASDAQ:LTRN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Connect Biopharma currently has a consensus price target of $7.43, indicating a potential upside of 193.62%. Given Connect Biopharma's stronger consensus rating and higher possible upside, research analysts clearly believe Connect Biopharma is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by company insiders. Comparatively, 8.5% of Lantern Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Connect Biopharma's return on equity of -147.87% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-147.87%	-112.79%
Lantern Pharma	N/A	-198.34%	-129.08%

In the previous week, Connect Biopharma had 3 more articles in the media than Lantern Pharma. MarketBeat recorded 7 mentions for Connect Biopharma and 4 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.94 beat Connect Biopharma's score of 0.68 indicating that Lantern Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantern Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantern Pharma has lower revenue, but higher earnings than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,654.81	-$55.48M	-$1.15	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A

Connect Biopharma has a beta of -0.23, meaning that its stock price is 123% less volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market.

Summary

Connect Biopharma beats Lantern Pharma on 10 of the 14 factors compared between the two stocks.

Get Lantern Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LTRN vs. The Competition

Export

Metric	Lantern Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$34.61M	$3.71B	$6.99B	$13.03B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-1.87	10.52	269.55	25.26
Price / Sales	N/A	1,290.58	597.75	101.23
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	4.66	17.50	13.08	6.33
Net Income	-$17.12M	-$13.32M	$3.45B	$347.70M
7 Day Performance	-5.59%	1.53%	1.02%	0.97%
1 Month Performance	-12.05%	1.39%	1.68%	0.92%
1 Year Performance	-40.92%	55.83%	67.42%	20.45%

Lantern Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LTRN Lantern Pharma	0.3108 of 5 stars	$2.65 +0.8%	N/A	-44.7%	$33.81M	N/A	N/A	20	News Coverage Earnings Report Gap Down
IFRX InflaRx	2.0558 of 5 stars	$2.00 +2.0%	$7.33 +266.7%	+146.3%	$141.69M	$30K	N/A	60
EQ Equillium	3.04 of 5 stars	$2.23 +1.8%	$7.57 +239.5%	+116.1%	$138.47M	$41.10M	N/A	40	News Coverage Positive News Earnings Report Analyst Upgrade High Trading Volume
NGEN NervGen Pharma	1.8962 of 5 stars	$1.74 +2.4%	$14.00 +704.6%	N/A	$137.07M	N/A	N/A	N/A	News Coverage Earnings Report
HURA TuHURA Biosciences	1.9881 of 5 stars	$2.30 +7.0%	$9.00 +291.3%	-19.0%	$136.92M	N/A	N/A	N/A	News Coverage Earnings Report High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LTRN) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lantern Pharma (LTRN) Competitors

LTRN vs. IFRX, EQ, NGEN, HURA, and CNTB

How does Lantern Pharma compare to InflaRx?

Summary

How does Lantern Pharma compare to Equillium?

Summary

How does Lantern Pharma compare to NervGen Pharma?

Summary

How does Lantern Pharma compare to TuHURA Biosciences?

Summary

How does Lantern Pharma compare to Connect Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LTRN vs. The Competition

Lantern Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lantern Pharma (LTRN) Competitors

LTRN vs. IFRX, EQ, NGEN, HURA, and CNTB

How does Lantern Pharma compare to InflaRx?

Do institutionals & insiders hold more shares of IFRX or LTRN?

Which has more risk and volatility, IFRX or LTRN?

Does the media refer more to IFRX or LTRN?

Is IFRX or LTRN more profitable?

Which has stronger valuation and earnings, IFRX or LTRN?

Do analysts recommend IFRX or LTRN?

Summary

How does Lantern Pharma compare to Equillium?

Which has better earnings & valuation, EQ or LTRN?

Do analysts recommend EQ or LTRN?

Does the media refer more to EQ or LTRN?

Is EQ or LTRN more profitable?

Do institutionals and insiders believe in EQ or LTRN?

Which has more volatility & risk, EQ or LTRN?

Summary

How does Lantern Pharma compare to NervGen Pharma?

Is LTRN or NGEN more profitable?

Do insiders & institutionals hold more shares of LTRN or NGEN?

Do analysts rate LTRN or NGEN?

Which has preferable valuation and earnings, LTRN or NGEN?

Does the media favor LTRN or NGEN?

Summary

How does Lantern Pharma compare to TuHURA Biosciences?

Does the media refer more to HURA or LTRN?

Do insiders and institutionals have more ownership in HURA or LTRN?

Which has more risk and volatility, HURA or LTRN?

Do analysts recommend HURA or LTRN?

Is HURA or LTRN more profitable?

Which has higher valuation and earnings, HURA or LTRN?

Summary

How does Lantern Pharma compare to Connect Biopharma?

Do analysts prefer CNTB or LTRN?

Do institutionals & insiders believe in CNTB or LTRN?

Is CNTB or LTRN more profitable?

Does the media favor CNTB or LTRN?

Which has higher valuation & earnings, CNTB or LTRN?

Which has more risk & volatility, CNTB or LTRN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LTRN vs. The Competition

Lantern Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools